Processing

Please wait...

Settings

Settings

1. WO2012168349 - COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Publication Number WO/2012/168349
Publication Date 13.12.2012
International Application No. PCT/EP2012/060782
International Filing Date 07.06.2012
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
4523
containing further heterocyclic ring systems
4545
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4709
Non-condensed quinolines containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
06
Antiasthmatics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
08
Bronchodilators
C07D 401/12 (2006.01)
C07D 409/14 (2006.01)
C07D 417/12 (2006.01)
A61K 31/4545 (2006.01)
A61K 31/4709 (2006.01)
A61P 11/06 (2006.01)
CPC
C07D 401/12
C07D 409/14
C07D 417/12
Applicants
  • CHIESI FARMACEUTICI S.p.A. [IT/IT]; Via Palermo, 26/A I-43100 Parma, IT (AllExceptUS)
  • RANCATI, Fabio [IT/IT]; IT (UsOnly)
  • LINNEY, Ian [GB/IT]; IT (UsOnly)
  • RIZZI, Andrea [IT/IT]; IT (UsOnly)
  • BLACKABY, Wesley [GB/IT]; IT (UsOnly)
  • KNIGHT, Chris [GB/IT]; IT (UsOnly)
Inventors
  • RANCATI, Fabio; IT
  • LINNEY, Ian; IT
  • RIZZI, Andrea; IT
  • BLACKABY, Wesley; IT
  • KNIGHT, Chris; IT
Agents
  • MINOJA, Fabrizio; Via Plinio, 63 I-20129 Milano, IT
Priority Data
11169535.910.06.2011EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
(FR) COMPOSÉS AYANT UNE ACTIVITÉ ANTAGONISTE DES RÉCEPTEURS MUSCARINIQUES ET UNE ACTIVITÉ AGONISTE DES RÉCEPTEURS ADRÉNERGIQUE BÊTA-2
Abstract
(EN)
The present invention relates to compounds of general formula (I), acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients.
(FR)
La présente invention porte sur des composés représentés par la formule générale (I), agissant à la fois comme antagonistes des récepteurs muscariniques et comme agonistes des récepteurs adrénergiques bêta-2, sur des procédés pour leur préparation, sur des compositions les comprenant, sur leurs utilisations thérapeutiques et des combinaisons de ceux-ci avec d'autres principes actifs pharmaceutiques.
Other related publications
Latest bibliographic data on file with the International Bureau